Form 4: GoodRx Grants Chief Accounting Officer 108,189 RSUs

GoodRx Holdings, Inc. reported that its Chief Accounting Officer, Romin Nabiey, was granted 108,189 restricted stock units.

Summary

• Romin Nabiey, Chief Accounting Officer of GoodRx Holdings, Inc., was granted 108,189 Restricted Stock Units (RSUs) on March 3, 2026.
• Each restricted stock unit represents a contingent right to receive one share of Class A common stock.
• The RSUs will vest ratably in 12 equal quarterly installments, with the first vesting occurring on April 15, 2026.
• Vesting is subject to Romin Nabiey's continued service through each applicable vesting date.
• Following this grant, Nabiey directly beneficially owns 175,748 shares of Class A Common Stock and 108,189 derivative securities (Restricted Stock Units).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, indicating executive retention and alignment of interests, which is generally favorable for corporate governance and long-term stability.

Positives

• The grant of 108,189 Restricted Stock Units (RSUs) to Chief Accounting Officer Romin Nabiey aligns management's long-term interests with those of shareholders.
• The vesting schedule over 12 equal quarterly installments promotes executive retention and sustained commitment to the company's performance.

Future Outlook

The vesting schedule for the granted Restricted Stock Units extends over 12 equal quarterly installments, with the first vesting on April 15, 2026, contingent upon Romin Nabiey's continued service to the company.

Industry Context

StockSavvy.ai notes that granting Restricted Stock Units is a common practice in the technology and healthcare industries to incentivize and retain key executives, aligning their long-term interests with shareholder value creation. This move by GoodRx is consistent with standard executive compensation strategies seen across its peer group.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) to a Chief Accounting Officer is a standard compensation practice, comparable to similar grants at companies like Teladoc Health (TDOC) or Livongo Health (LVGO) before its acquisition, which frequently use equity awards to retain top talent.
• The vesting schedule of 12 equal quarterly installments over three years is a typical long-term incentive structure, similar to those observed at major tech and healthcare firms, ensuring sustained commitment from the executive.

Stakeholder Impact

• Shareholders: The grant aligns the Chief Accounting Officer's long-term interests with shareholder value through equity ownership, potentially leading to more stable and focused management.
• Employees: Retention of key executives like the Chief Accounting Officer can signal stability and positive internal outlook.

Next Steps

• Continued service by Romin Nabiey through each applicable vesting date for the Restricted Stock Units.
• Quarterly vesting of the Restricted Stock Units, commencing April 15, 2026.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a key executive, which is a positive for executive retention and alignment. However, it does not present new information significant enough to alter the fundamental investment thesis or warrant a change in recommendation for the stock based solely on this filing. It reinforces a 'hold' stance as a standard operational event.

Keywords

GoodRx Holdings, GDRX, Restricted Stock Units, RSU Grant, Insider Transaction, Form 4, Executive Compensation, Romin Nabiey, Chief Accounting Officer